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This article is part II of a mini-monograph on
the many facets of a little-discussed but
important aspect of the overall issue of phar-
maceuticals and personal care products
(PPCPs) as environmental pollutants: pollu-
tion prevention. In light of the fact that trace
residues from this large, diverse galaxy of
sometimes highly bioactive chemicals gain
entry to the environment simply by way of
their use and disposal (Daughton 2001a;
Daughton and Jones-Lepp 2001; Daughton
and Ternes 1999; Heberer 2002; Kolpin et al.
2002; Kümmerer 2001; Servos et al. 2002),
and regardless of what little is known regard-
ing the consequences for ecologic or human
health (Daughton 2001a; Daughton and
Ternes 1999), a wide spectrum of actions can
be taken to minimize or eliminate their fur-
ther environmental disposition. Signiﬁcantly,
these actions toward pollution prevention
(e.g., source reduction/control) hold the
potential at the same time for beneficial
human health consequences unrelated to their
occurrence as pollutants (Daughton 2002).
This second of two parts focuses on those
source control/reduction activities tied more
closely to the end user (e.g., the patient and
consumer) and issues associated with drug
disposal/recycling rather than those that reside
more under the control of the health care
industry (further up the chain of events
involved with a drug’s cradle-to-grave disposi-
tion), which is the focus of part I (Daughton
2003). In this second part, I also outline some
specific suggestions centering more on end
use, present recommendations for further
research, and pose some considerations
regarding the future; the background and con-
text for why pollution prevention is a topic
worth considering for PPCPs are covered in
part I.
Drug Disposal/Recycling/
Pollution Prevention
Responsible disposal and product stewardship.
Of all the inquiries received from the public
and the news media on the topic of PPCPs in
the environment, the most frequent regards
“proper” (ecologically sound) disposal of
unused medications. Unfortunately, deﬁnitive,
consistent guidance is not available. The age-
old wisdom of ﬂushing medication down the
toilet (still recommended by many profession-
als), however, is probably the least desirable of
all the alternatives, which include disposal in
household trash and community hazardous
waste pickup programs. Indeed, standardized
nationwide or international guidance is needed
for disposition of noncontrolled substances by
end users of unused/expired drugs as well as by
disposal companies. A formal but voluntary
Product Stewardship program (previously
known as Extended Product Responsibility;
Hanisch 2000; U.S. EPA Office of Solid
Waste 2002) implemented by all involved
industries would be a proactive way to guide
the disposal of unwanted, expired (“outdated”)
PPCPs by the public, state, local, and medical
communities (e.g., nursing homes, hospitals,
physician samples). National policies are usu-
ally directed solely at the internal generation of
wastes by the medical care industry—not by
the public. For example, Australia [National
Health and Medical Research Council
(NHMRC) 1999] advises, “Wherever possible,
this waste should be incinerated. It should not
be sent for landﬁll. Such waste should not be
discharged into sewerage systems” (p. 14).
Little exists in the peer-reviewed literature
regarding drug disposal regulations and atten-
dant issues. Within the gray literature (i.e., lit-
erature not captured by traditional means of
archiving), four of the more informative
resources are Musson and Townsend (1998),
Smith (2002), Wang (2000), and the World
Health Organization (WHO 1999). The ideas
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Since the 1980s, the occurrence of pharmaceuticals and personal care products (PPCPs) as trace
environmental pollutants, originating primarily from consumer use and actions rather than manu-
facturer efﬂuents, continues to become more ﬁrmly established. The growing, worldwide impor-
tance of freshwater resources underscores the need for ensuring that any aggregate or cumulative
impacts on (or from) water supplies are minimized. Despite a paucity of effects data from long-
term, simultaneous exposure at low doses to multiple xenobiotics (particularly non-target-organ-
ism exposure to PPCPs), a wide range of proactive actions could be implemented for reducing or
minimizing the introduction of PPCPs to the environment. Most of these actions fall under what
could be envisioned as a holistic stewardship program—overseen by the health care industry and
consumers alike. Significantly, such a stewardship program would benefit not just the environ-
ment—additional, collateral beneﬁts could automatically accrue, including the lessening of med-
ication expense for the consumer and improving patient health and consumer safety. In this article
(the second of two parts describing the “green pharmacy”) I focus on those actions and activities
tied more closely to the end user (e.g., the patient) and issues associated with drug disposal/recy-
cling that could prove useful in minimizing the environmental disposition of PPCPs. I also out-
line some recommendations and suggestions for further research and pose some considerations
regarding the future. In this mini-monograph I attempt to capture cohesively for the ﬁrst time the
wide spectrum of actions available for minimizing the release of PPCPs to the environment. A
major objective is to generate an active dialog or debate across the many disciplines that must
become actively involved to design and implement a successful approach to life-cycle stewardship
of PPCPs. Key words: cradle-to-cradle stewardship, drugs, environmental pollution, green phar-
macy, pollution prevention. Environ Health Perspect 111:775–785 (2003). doi:10.1289/ehp.5948
available via http://dx.doi.org/ [Online 12 December 2002]
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incidentally, have evolved separately from
those of “industrial ecology,” but the principle
of closing the loops for material ﬂows is shared
by both. The ﬁrst professional society devoted
to industrial ecology, the International Society
for Industrial Ecology, was recently formalized
(International Society for Industrial Ecology
2001).
Incentives. One of many possible ap-
proaches to fostering stewardship programs
[those that tie both environmental and
human health together—“ecology of health”
(Daughton 2003)] would be to offer patent
extensions to companies that formulate
vibrant, comprehensive stewardship programs
tailored for each particular drug. Precedent
for this resides in what was the U.S. Food and
Drug Administration (FDA)’s Pediatric Rule
[an incentive-based rule that encouraged clini-
cal trials designed for children (Center for
Drug Evaluation and Research; CDER 2002),
since replaced by the Best Pharmaceuticals for
Children Act (U.S. FDA 2002a), which offers
6-month patent extensions for doing research
that defines safe dosages for children.
Interestingly and ironically, the rationale for
this need is that it is not possible to predict
the differing responses of children (compared
with adults)—the same as what might very
well be true for potential effects on nontarget
organisms.
Expanded use and mission of reverse
distributors. Many but not all U.S. pharma-
cies use “reverse distributors” for return of
unsold/expired inventory [e.g., Returns
Industry Association (RIA) 2002;
RxWebPortal.com 2002]. This existing indus-
try could serve as the foundation for an over-
arching returns industry—by its expansion
into a larger, comprehensive disposal/recycling
program, one that accommodates the con-
sumer sector. Great value could be added by
designing an integral database that compiled
information mined from consumer returns,
with the objective of ultimately improving
health care; such data are traditionally
extremely difﬁcult to obtain.
Pharmaceutical “returns” result directly
from the many issues associated with
“unsaleables” (products unwanted by the con-
sumer, for any of a wide spectrum of reasons,
and products that have expired), a topic
whose entire scope is not even understood by
the involved industries, but one that has been
captured in a report by Siecker (2001). The
monetary costs associated with returns in the
United States have been estimated at up to
(or even exceeding) $2 billion per year,
exceeding the actual market value of the
products (Siecker 2001); these costs, however,
have never been factored in to a cradle-to-cra-
dle approach. Clearly, many inefficiencies
exist in the distribution system. The many
forces that cast a product into the unsaleable
class have been enumerated by Siecker
(2001); these range from simple expiry issues
to new market forces (rapid obsolescence by
market-entry of new products) to seasonal
demand. Industry has brainstormed on ways
to reduce the need for returns (Siecker 2001),
and some of the ideas correspond with those
presented in this mini-monograph. That the
returns industry is so large and that it is dri-
ven by the many vagaries of consumerism
perhaps cast some light on the scope and
magnitude of the parallel issues with con-
sumer creation of unused drugs. The total
cost for drugs that are placed into the returns
network amounts to a little more than 1% of
total sales. The 2002 Chain Pharmacy
Industry Profile [National Association of
Chain Drug Stores (NACDS) 2002] reports
US$164 billion in 2001 total retail pharmacy
sales resulting from more than 3 billion pre-
scriptions, representing 2-year increases of
13–16% in sales and 5–6% in scripts; $188.5
billion in sales are projected for 2002 (a 15%
increase from 2001). Four of every five
patients leave the doctor’s office with a pre-
scription (NACDS 2002), so the distribution
of drugs through the consumer sector is
clearly enormous.
Physician samples. Although physician
samples (manufacturer samples distributed
free to medical practices) constitute an
unknown percentage of the overall disposal
problem, distributors of physician samples
often instruct physicians to dispose of out-
dated samples to the sewage system. This
source should also be subject to any nation-
wide guidance or regulations.
Source separation for domestic wastes.
Advancement in, and implementation of, new
technologies for dealing with waste at the
source (e.g., separation of distinct streams)
holds the highest potential for the future min-
imization of waste ﬂows to the environment.
Sewage source separation schemes such as
those involving toilet reengineering are
but one example (e.g., Larsen et al. 2001;
Novaquatis 2002; Otterpohl 2002).
Sewage recycling. Also under development
are various “toilet-to-tap” plans for upgrading
sewage to potable water (or at least to a level
suitable for groundwater reinjection) (Drewes
and Shore 2001; Greene 2000). By use of
advanced water treatment technology such as
reverse osmosis, nearly complete removal of
all PPCPs can be achieved. However, all the
solutes removed by reverse osmosis are con-
centrated in the rejected “brine”—a waste
stream that must be disposed itself.
Improvements to sewage infrastructure.
Straight-piping of sewage (e.g., Pressley 1999)
to surface waters should continue to be identi-
fied and eliminated on an ongoing basis.
Privies and septic systems should be converted
to municipal systems when feasible. Im-
provements in capacity can reduce overflow
events, a problem of escalating proportions in
many urban areas (e.g., see one of an extensive
news series on aging sewer infrastructure in
Sforza et al. 2001). It has long been assumed
that ocean discharge of sewage protects coastal
exposure (by way of dilution). A recent study,
however, shows the possibility of sewage plume
redirection to coastal areas by tidal events
(Boehm et al. 2002). As sewage discharges
increase with expanding populations, the dilu-
tion previously afforded by receiving waters
will continually diminish.
Recycling (reclamation). “Drug mining,”
such as hospital reclamation of highly toxic
drugs from excreta and other wastes, could be
pursued and expanded; a prototype example
can be found in work by Pharmaceuticals.org
(2002).
Responsible reuse, recycling, and donation.
The entire area of charitable drug donations
and pharmacy reuse (sometimes referred to as
recycling) is a complex issue fraught with con-
cerns, especially regarding safety, liability, and
compensation. Donations are complicated by a
morass of international regulations, politics,
interconnected organizations and charities, and
controversy (Reich 1999). One of the technical
issues associated with drug donations and reuse
is that of expiry. More information can be
found at the website maintained by the
Wemos Foundation (2002). Certain state leg-
islation in the United States (e.g., Ohio
General Assembly 2001) has been attempting
to establish drug “repository” programs for col-
lecting and redistributing unadulterated pre-
scription drugs for subsequent represcribing to
patients meeting eligibility requirements.
The reuse by pharmacies of previously
prescribed, within-date drugs has been a con-
tentious and complex issue for more than two
decades—partly because of the rising costs of
new-generation drugs and because of insufﬁ-
cient public resources dedicated to the med-
ically indigent. There is also debate over who
should benefit (in terms of compensation)
from reuse, given that the original patients,
insurance companies, or Medicaid programs
originally paid for the unused medications.
Dispensing laws often run counter to
responsible reuse of still-usable drugs (OSU
2000a) despite the fact that modern, tamper-
evident packaging would greatly assist in the
assurance of the quality of reused drugs. In
Oklahoma alone, long-term care facilities
(LTCFs) each month are directed by state law
to dispose of millions of dollars of unused
medications (and incur substantial personnel
oversight/implementation costs); an unknown
portion of the disposed drugs is directed to
municipal sewers (OSU 2000a). At the same
time, the medically indigent often do not
receive medications that they may require,
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public funds (OSU 2000a).
One rough estimate of the national mone-
tary value of unused drugs in LTCFs is
US$73–378 million (OSU 2000a); statistically
based estimates are difficult to compile
because of the proprietary nature of the indus-
try. This estimate assumed wastage rates of
4–15%, which have been revealed by various
state studies (OSU 2000a).
It is illegal in certain states (e.g., Okla-
homa) to give away (e.g., donate to charity)
any drug already obtained by prescription
(OSU 2000a, 2000b). It is also illegal in cer-
tain states for pharmacies to accept returned
unused drugs; this is a result of long-recog-
nized, complex issues regarding quality assur-
ance (particularly problematic is a drug’s shelf
history—whether it was stored in a controlled
environment, especially regarding tempera-
ture and humidity—as well as the issue of
counterfeiting). Because of these complicating
factors, the FDA has no general policy gov-
erning reuse and instead prefers that each
state set its own individual policy (OSU
2000b); the FDA does not disallow reuse—it
simply highlights the dangers and pitfalls that
require vigilance in establishing a reuse pro-
gram. The American Medical Association
(AMA) supports the reuse of drugs in LTCFs
(AMA 2001). In light of this, it behooves the
states to study and emulate best practices and
try to align their practices accordingly.
Demonstrating the disparate implementa-
tion of drug reuse across the United States, it
has proved difﬁcult to ascertain exactly what
state practices do entail. One survey maintains
that as of the year 2000, 36 states allowed at
least some form of drug reuse (recycling) or
resale; 17 allowed both reuse and resale with-
out restrictions, and 12 prohibited any reuse
or resale (OSU 2001, 2000b). A subsequent
survey (OSU 2001), however, revealed only
six or so states with reuse/resale provisions. It
is clear that the issue is complex, with different
meanings, interpretations, and implementa-
tion across the states. Certain states have been
actively working on legislation that would
enable reuse; Ohio (Ohio General Assembly
2001) and Oklahoma (OSU 2001) are
two examples.
Environmentally sound funeral practices.
In countries practicing burial, cemeteries
[which are a special landfill subclass (Ucisik
and Rushbrook 1998)] can pose problems
with respect to groundwater pollution if they
have not been properly engineered and sited
with local hydrogeologic processes in mind
(Croukamp 1999). Although a number of
investigations have examined the transport of
pathogens from burial grounds to the ground-
water (Santarsiero et al. 2000), little is known
regarding the release of PPCPs, whose pres-
ence in dead bodies could be expected to be
extensive as a result of long-term medication
and heroic treatment measures. Furthermore,
in North America, those areas where embalm-
ing is practiced commonly discharge with-
drawn body fluids (containing whatever
medications the dying patient had been
administered) directly into municipal sewage
systems (Funeral Consumers Alliance 2002).
An analogous problem might exist with the
disposal of carcasses from medicated or eutha-
nized pets (see Daughton 2001a), where
lethal concentrations of barbiturates such as
sodium pentobarbital are often used.
Public outreach/education—heightening
public awareness. A well-designed, concerted
public outreach program for communicating
the issues associated with PPCPs as environ-
mental pollutants could accomplish dual aims:
a) enhance the public’s appreciation and
understanding of a wide range of principles
associated with environmental science, and
b) increase the public’s sense of environmental
responsibility by showing how their actions as
individuals collectively contribute to the bur-
den of PPCPs in the environment, how PPCPs
can possibly affect environmental processes
(e.g., aquatic biota), and the collateral advan-
tages (human health and economic) accrued by
conscientious/responsible disposal and use of
PPCPs. The educational aspects of the topic
are summarized in Daughton/U.S. EPA
(2002a).
Two additional potential opportunities
exist with leveraging the public education
aspect of PPCPs as environmental pollutants:
First, the fact that drugs can theoretically be
monitored in sewage now provides society for
the ﬁrst time with the science to quantify the
actual extent and magnitude of community-
wide use of illicit/abused drugs (Daughton
2001b); this would objectify the decades-old
and emotionally charged national debate
regarding the actual magnitude of drug abuse.
Second, parallel to this is the fact that monitor-
ing for illicit drugs in sewage or the environ-
ment could raise community awareness of
inadvertent financial support to terrorism
(Daughton/U.S. EPA 2001a; ONDCP 2002).
These activities, in turn, would heighten the
public’s awareness that their combined, daily
individual activities, actions, and behaviors can
have immediate, intimate, and inseparable
connections with the environment and with
world events. With improved knowledge of
these connections, behaviors (e.g., con-
sumerism) affecting pollution prevention, dis-
posal, and recycling may eventually become
self-adjusting or self-regulating.
Drug Alternatives
A variety of alternatives to drug therapy, rang-
ing from nutrition to advanced use of medical
microbial ecology, could help reduce society’s
use of medications.
Nutrition and health maintenance. The
key and critical disease-prevention role played
by nutrition should continue to be explored
and emphasized at all levels. A number of fed-
eral agencies and organizations are active in
purveying information regarding the critical
linkage between nutrition and health (wellness
or disease prevention), including the U.S.
Centers for Disease Control and Prevention
(CDC 2002a), Health Canada (2002), and
the U.S. Department of Agriculture (USDA
2002a, 2002b). This type of information
could be made an integral, visible part of
direct-to-consumer advertising for drugs
(Daughton 2003). The connections between
health maintenance/improvement via proper
nutrition and the reduced need for medication
are well documented.
Placebos. Although “alternative” medicine
(e.g., standardized, bioactive, naturally occur-
ring substances such as phytochemicals and
other “nutraceuticals”) has received much
renewed attention (Daughton and Ternes
1999) and could eventually reduce the use of
synthetic drugs, more emphasis could be
placed on expanding the exploration of non-
chemical alternatives to traditional medica-
tions. As an example, more research could be
directed at reducing (or eliminating) drug
dosages via the use of placebos (e.g.,
Christensen 2001; Leuchter et al. 2002).
Probiotics. Probiotics (beneﬁcial, endoge-
nous microflora) have long been used and
studied for the protection of the gut [largely by
blocking pathogen adhesion (e.g., Kaur et al.
2002)]. More recent work has expanded this
important domain of clinical microbial ecology
to other medical uses such as prophylaxis for
postsurgical infection [in lieu of prophylactic
antibiotics (e.g., Harder 2002; Reid et al.
2001)]. The U.S. FDA Center for Veterinary
Medicine approved the ﬁrst probiotic for ani-
mals (known as a “competitive exclusion cul-
ture” product) in 1998; still the only approved
competitive exclusion product, it is known by
the trade name Preempt, and its New Animal
Drug Application number is 141-101 (U.S.
FDA 2002b). Sometimes called “bacteriother-
apy,” the wide range of medical uses of probi-
otics for displacing pathogens is summarized in
Beale (2002).
Research and Development
Further research and development on a wide
range of fronts could contribute to the mini-
mization of PPCPs in the environment.
Several are summarized here.
Determining the relative importance of
sources. Disposal versus excretion/washing.
Determine the relative contributions to envi-
ronmental loadings of PPCPs from direct,
purposeful disposal to sewage (and trash) of
unwanted/unused PPCPs versus inadvertent
excretion and washing. That portion of the
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from direct disposal versus end use is totally
unknown. More extensive public surveys and
actual monitoring could be used to tease these
apart. For example, for those oral drugs that
a) are efficiently absorbed and undergo
extensive, nearly complete metabolism excrete
low levels of the parent form (e.g., imipra-
mine, morphine, itraconazole, isoproterenol,
meperidine, verapamil, among many) and
b) also are documented to occur in the envi-
ronment, perhaps it could be concluded that
direct disposal plays a signiﬁcant role in their
entering the environment. Bathing would be
expected to be the most signiﬁcant source for
those drugs that are extensively applied exter-
nally (e.g., silver sulfadiazine burn cream) and
other topically applied antibiotics (e.g., baci-
tracin) as well as for personal care products
(e.g., synthetic musk fragrances), but disposal
could play a role.
Disposal from LTCFs versus general
population. The accumulation of unused
medications at LTCFs presents major, well-
documented problems for disposal. It is not
known, however, how signiﬁcant this source
is compared with disposal from the general
populace. This issue grows more important as
our population’s age structure becomes more
inverted.
Maintenance versus short term. The rela-
tive overall contributions to the environment
by long-term maintenance drugs (used exten-
sively at LTCFs) versus short-term drugs is
not known.
Hospitals versus domestic. The use of
on-site waste reclamation and treatment varies
greatly for hospitals and other medical care
facilities. Hospitals especially might be
expected to be more significant contributors
for certain highly toxic drugs such as antineo-
plastics and other cytotoxic drugs.
Domestic animals versus humans. We
should attempt to determine the relative con-
tributions from veterinary animals (e.g., con-
ﬁned animal feeding operations, aquaculture,
pets) versus that for humans. This is especially
important regarding steroids (e.g., Renner
2002) and antibiotics (certain antibiotics and
anabolic steroids are used exclusively for vari-
ous domestic animals), where the overall load-
ings could be important. Although the
discussion in this article has focused on
human therapeutics, veterinary drugs clearly
can be major contributors to environmental
exposure (e.g., see Boxall et al. 2002).
Straight-piping and raw sewage versus
treated sewage. Straight-piping sidesteps ben-
eﬁts that might exist in secondary and tertiary
sewage treatment for further drug removal, so
the relative contributions from straight-piping
versus those for treated sewage would be use-
ful to know. Overflow discharge of raw,
untreated sewage is becoming more prevalent
as aging and under-capacity treatment plants
cannot keep pace with urban populations.
Waivers for over-capacity overflows are fre-
quently granted for discharges to marine envi-
ronments, in contrast to straight-piping and
malfunctioning septic systems, which can be
found discharging into any type of receiving
water. Another potential source of PPCPs
from raw sewage (although more geographi-
cally confined) is cruise ships, which have a
history of discharge of insufficiently treated
sewage (Alaska Department of Environmental
Conservation 2001a, 2001b, 2002; Nowlan
and Kwan 2001).
Illicit versus licit drugs. The prevalence of
illicit drugs in the environment is completely
unknown (Daughton 2001b). Although the
occurrence database for licit drugs continues
to be expanded, with new publications
appearing frequently, almost no effort has
been devoted to illicit drugs.
Effect of health status on excretion.
Health or disease status probably has a large
but undetermined signiﬁcance with respect to
determining the extent of excretion of drugs
in their unaltered states. Gastrointestinal dis-
ease can dramatically reduce uptake and
thereby enhance excretion (or expulsion, e.g.,
through vomiting) of the parent drug.
Sequestration (e.g., chelation of tetracycline
by dairy products or of fluoroquinolones by
divalent cations), alteration in gastrointestinal
mobility, or alteration of gastric pH can simi-
larly alter excretion. A better understanding of
these parameters for the individual patient
not only would better serve patients (e.g., by
altered delivery routes) but also could reduce
unnecessary excretion.
Release into waters with low versus high
existing pollutant loads. An argument can be
made that windows of aquatic toxicity vulner-
ability open as a dynamic function of the rate
of change or status of overall cellular stress.
Organisms that have accommodated to new
stress (e.g., by synthesis of cellular stress pro-
teins or overexpression of efﬂux pumps) may
be signiﬁcantly more resistant to the effects of
newly present toxicants than those organisms
equilibrated to a constant environment. For
this reason, organisms in slowly changing,
pristine environments may be more suscepti-
ble to new exposure to chemical stressors than
are organisms experiencing ongoing exposure
to many, changing stressors.
New drugs and ecotoxicology. Regardless
of the environmental signiﬁcance of the cur-
rent universe of drugs, the anticipated contin-
uing expansion in new drug entities (those
from new chemical classes and with previously
unknown mechanisms of action—whose
development will be driven largely by
advancements on the many fronts of “omics”)
provides the opportunity to develop ecologic
toxicity testing approaches that are more capa-
ble of detecting the types of effects that could
ensue. Particular attention should be paid to
accounting for shared mechanisms of action
(to accommodate cumulative exposure; see
Daughton 2003, Figure 2). Also needed is
attention to chemicals that are not necessarily
toxic in their own right but can potentiate the
toxicity of other substances (“chemosensitiz-
ers”). A good example of this concern is the
possible need to screen for a pollutant’s poten-
tial to inhibit multidrug efﬂux pumps, which
serve as the first lines of defense for aquatic
organisms (Daughton 2001a; Daughton and
Ternes 1999; Epel and Smital 2001); this
would obviously be important for the new
generations of efflux pump inhibitors them-
selves but also would apply to any PPCP hav-
ing efﬂux-pump inhibition potential. As just
one example of a new therapeutic class of
drugs that may pose environmental concern,
consider the angiogenesis inhibitors (see links
at NCI 2003). This broad therapeutic class
consists of a number of synthetics—including
legacy drugs such as thalidomide, as well as
many new ones. These compounds have pro-
found teratogenic potential (thalidomide
being a well-known example), but little
is known about their aquatic toxicology
(especially important during embryogenesis
and development).
Early warning monitoring. A nationwide,
universal early-warning water monitoring
system that can detect any newly appearing
xenobiotic (including PPCPs) would be
tremendously useful for detecting new trends
(including illicit drugs) and for permitting
early intervention as needed before adverse
impacts might occur. A proposal on the utility
of an early-warning monitoring system based
solely on the simple approach of identifying
anomalous constituents exclusively (largely
ignoring all pre-existing constituents) has been
outlined (Daughton/U.S. EPA 2001b). A col-
lateral beneﬁt from a real-time early-warning
monitoring system is that it could be easily
designed to serve double duty for homeland
security—to detect any newly present chemical
sabotage agent. A monitoring system is also a
key component of any effort to measure the
effectiveness of pollution prevention strategies
that have been implemented [in keeping with
the U.S. EPA’s new Innovation Strategy
(Gibson 2002; U.S. EPA 2002)]. In recent
years, there have been a number of proposals
for creation of a national health monitoring sys-
tem—one based on epidemiology and environ-
mental monitoring, illustrated recently by a
meeting sponsored by the Institute of
Medicine’s Roundtable on Environmental
Health Sciences, Research, and Medicine (IOM
2002). A nationwide early-warning monitoring
system for previously unrecognized or newly
emerging pollutants could be integrated within
such a system. Furthermore, the system could
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ronmental health in addition to human health
pollutants because the argument can be made
that the two are inseparable (Daughton 2003).
Guidance on groundwater recharge. With
dwindling supplies of potable water supplies in
many parts of the world, efforts to recycle
water are accelerating (Drewes and Shore
2001). One approach is to store treated sewage
in aquifers by a variety of active reinjection or
recharge approaches. Although this approach
seems straightforward, the fact that the envi-
ronmental half-lives of many substances are
increased in the subsurface domain (because of
reduced microbial activity, lack of photolytic
alterations), it is imperative that reinjected
water be cleaned to standards protective of eco-
logic and human health. Consistent, national
guidance (but which can be tailored to local
geology) is therefore needed regarding the
composition of active recharge waters.
Extended expiry. Extend the shelf life
research already being performed for factory-
sealed drugs under the Shelf-Life Extension
Program (Daughton 2003) to see if expiration
dates on public-sector factory-sealed drugs and
pharmacy-dispensed drugs can be extended
or maximized.
Excipients and “alternative” medicines.
Even though registered drugs and diagnostics
have a paucity of data regarding potential or
actual environmental effects (other than for
conventional ecotoxicologic tests), excipients
(the nontherapeutic agents in formulated med-
icines), alternative drugs such as nutraceuticals
and dietary supplements, and personal care
products (except the synthetic musk fra-
grances, some surfactants, and sunscreen
agents) have even less. Some research effort
should be devoted to these underinvestigated
classes of PPCPs in the environment to gage
their possible importance. The diverse classes
of bioactive chemicals in nutraceuticals and
dietary supplements are growing as a result of
renewed interest in “self-care.” Several exam-
ples are summarized by Daughton and Ternes
(1999). In contrast to the use of pharmaceuti-
cals (with the exception of “cosmetic” or
“lifestyle” pharmaceuticals), consumer use of
personal care products is almost always one of
personal discretion. Also unlike pharmaceuti-
cals, most personal care products are used
externally (or not ingested) and in larger quan-
tities, maximizing their likelihood for release to
the environment (via bathing or oral discharge).
Future Concerns/Opportunities
Molecular farming (“pharming”). The large-
scale production (kilograms per hectare) of
pharmaceuticals by transgenic organisms,
especially plants and food crops (known as
molecular farming or “pharming”), is cur-
rently aimed mainly at producing phytophar-
maceuticals—“functional foods,” “biologic”
and other medically related reagents, diagnos-
tics, and vaccines. Today, molecularly farmed
pharmaceuticals are primarily recombinant
proteinaceous therapeutics, such as enzymes,
hormones, and monoclonal antibodies, that
tend to be costly to produce by existing
means (e.g., cultured mammalian cells) and
more risky because of transference of human
pathogens. For a listing of relevant web
resources and reports on plant-made pharma-
ceuticals, see Daughton/U.S. EPA (2002b).
Although these current-generation phy-
topharmaceuticals are proteins (and therefore
at least have an innate susceptibility for degra-
dation in the environment), questions must
be asked as to the wisdom of mass biosynthe-
sis of pharmaceuticals in food plants, whether
the large quantities that can be produced will
have the ability for direct escape to the envi-
ronment (with the attendant unknowns of
persistence and nontarget, unanticipated
effects), and whether the technology will
eventually gain the routine ability to synthe-
size small-molecule nonproteins, which may
pose different concerns than for proteins.
Contamination of the common agricul-
tural food-plant gene pool by cross-pollina-
tion has been established as a major concern
(albeit hotly debated), especially if the thera-
peutic is bioactive at trace concentrations
(e.g., hormones). This concern is reﬂected by
the current U.S. regulations on intercrop dis-
tances and crop-cycle timing, as stipulated in
regulations by the USDA (via the Animal and
Plant Health Inspection Service) and the U.S.
FDA (see links at Daughton/U.S. EPA
2002b). Furthermore, the crops most fre-
quently used for molecular farming are corn,
soybeans, and rice. Any progress in eliminat-
ing (vs. minimizing) the possibility of cross-
pollination would be desirable—a true
closed-loop system would be preferable
because any controversy regarding contamina-
tion of the common food supply would then
be negated. Although the primary concern
regarding risk has focused on humans (cen-
tered around allergenicity, and toxicity in the
form of direct endocrine disruption or other
mechanisms), perhaps more imminent (but
largely unanticipated) hazards could be pre-
sent for nontarget organisms, whose interac-
tions with crops are extremely difficult to
prevent. Any failure of the systems in place to
ensure the complete containment of plant-
made pharmaceuticals could at the least lead
to widespread distrust (and disruption) of the
long-established and trusted U.S. food indus-
try. Such concerns would at the least affect
mass psychology. As an example, although a
low level of contamination of nongenetically
modiﬁed foodstuffs with herbicide-tolerant or
insecticidal grain may be tolerable to some
people, would the same level of tolerance con-
tinue if a drug for rheumatoid arthritis or a
vaccine for hepatitis B were the contaminant?
For in-depth discussions of the many complex
facets of this topic, see CFIA (2001); Freese
(2002); Golz (2001); Kirk (2001); McCalla et
al. (2002); Pew Initiative (2002); see also
other resources at Daughton/U.S. EPA
(2002b).
Omics. As pointed out by Daughton and
Ternes (1999), rapid and escalating advance-
ments in genomics, proteomics, glycomics,
and others, coupled with an inverting societal
age structure, will contribute greatly to the
commercial introduction of an ever-increas-
ing array of new drug entities, many of which
target new receptors and possess previously
unforeseen mechanisms of action. As an
example, novel (non-native, “mutated”) pro-
teins can now be theoretically engineered
(using native biochemical machinery) by
modiﬁcation of existing proteins and incorpo-
ration of non-natural amino acids (e.g.,
Bessho et al. 2002). These “mutated” proteins
may not be as easily catabolized as native pro-
teins and therefore may have the potential for
longer ecologic half-lives. This fact, in light of
the precautionary principle, provides ample
forewarning to institute measures for mini-
mizing the risks that might be associated with
introducing drugs to the environment—and
at the same time improves consumer health
and economy.
Personal “medical statistics card.” A volun-
tary, personal “medical statistics card” contain-
ing an individual’s medical treatment history
could help minimize the overuse and inappro-
priate use of prescription drugs. The history
stored on such a card (including, e.g., past and
present medication, allergies) could assist an
attending physician prevent redundant or ill-
advised prescribing because of a lack of patient
data; this would be especially valuable for those
patients having multiple physicians and those
who “self-medicate.” It could even be used to
help consumers in prescreening over-the-
counter (OTC) drugs and food supplements
that could lead to adverse interactions with
prescription medication they are taking.
Consumers would not need to understand the
status of any of the medications and supple-
ments they are taking as long as they were dili-
gent in using their card when purchasing
medications or supplements; the card would
rely on accessing a standardized, up-to-date
expert system of prescribing information. Such
a card, whose information content could be
stored anonymously (no need to encode with
personal information) would not be confused
with the concept long and hotly debated in the
United States of a “national health card,”
which is intended more for obtaining medical
services rather than ensuring efﬁciency and efﬁ-
cacy of medical treatment; national health
cards have been successfully implemented for
some time in a number of other countries but
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because of real or perceived issues with privacy
protection. Patients could, however, also elect
to store medical information keyed to their
personal identity if they wished to avoid
repeated requests for the same information by
multiple medical care providers (and thereby
also ensure a more accurate, thorough, and
consistent portrayal of their medical histories
across a continuum of providers).
Insights and Recommendations:
Disposal of PPCPs by the End
User
In North America, only a fragmented patch-
work of often-contradictory regulations, guid-
ance, and formal/informal advice attempts to
direct the purposeful disposal of PPCPs. This
uncoordinated guidance is geographically
uneven and varies greatly among governing
bodies. Regardless of what the best environ-
mental disposition of expired/unwanted
PPCPs might eventually be, clearly there
would be beneﬁts in having but one optimal
approach. Much work is needed in formulat-
ing a single, cohesive set of nationwide (or
global) regulations or guidance addressing dis-
posal or recycling. Comprehensive regulations
or guidance would address PPCPs that have
entered the consumer chain, as well as those
used in hospitals, medical practices (e.g.,
physician’s samples), LTCFs (e.g., nursing
homes), and humanitarian relief efforts.
Locating literature regarding drug disposal
is not easy, primarily because there are no
unique search words. To broaden success in
key word searching of English documents
available on the Internet and published in the
printed literature, multiple terms must be
used, including the coupling of the words
“drug,” “medicine” (or the adjective “medica-
tion”), or “pharmaceutical” with “disposal,”
“destruction,” “recycling,” “reuse,” “return,”
“take-back,” “outdated,” or “expired.” Once
formal disposal/recycling program names
have been identified (e.g., EnviRx or RUM,
discussed below), they can be used in turn to
locate many more references (this is especially
useful for non-English-language web pages).
Current practice: patchwork of diametri-
cally opposed approaches. To illustrate the
disharmony of current practices, consider the
following: Most existing laws directed at drug
disposal are written around two concerns:
a) the disposition of “controlled” substances or
b) the imperative to keep expired/unwanted
medication away from children (this is perhaps
the major imperative for disposing of drugs to
sewage that has been instilled in the public
over the years). Environmental concerns are
rarely cited (in the United States, California is
one exception). Some states require nursing
homes to dispose of unwanted drugs to the
“toilet.” For example, State of North Carolina
(2002) regulations stipulate that “non-con-
trolled substances shall be disposed of by incin-
eration, ﬂushing into septic or sewer system, or
by transfer to a local pharmacy for destruc-
tion.” Many pharmacy or health care websites
recommend disposal to the sewer. Typical
examples include “flush old drugs down the
toilet; don’t just toss them in the trash where
little hands could get hold of them” (MSN
2002), and the California Poison Control
System (2002), advocates ﬂushing unwanted
drugs down the toilet. Sometimes, the advice is
nebulous and circular: “Contact your state
board of pharmacy or your state Environmental
Protection Agency office for the appropriate
means of disposal of prescription samples. Local
law enforcement may not be aware of speciﬁc
disposal issues relating to prescription drugs”
(Volunteers in Health Care 2001). In contrast,
other websites give more proactive advice. For
example, Great Paciﬁc Industries’ (2002; e.g.,
Save-On-Foods) pharmacy network has its
own “take-back” program, more in line with a
nationwide program that has been imple-
mented in Canada since the mid-1990s and in
Australia since 1998.
Take-back programs. Most British Co-
lumbia pharmacies belong to the Medications
Return Program (MRP). The MRP was insti-
tuted in March 2001 as a relaunch of the for-
merly known EnviRx program, which was
founded in November 1996 as a consumer-ori-
ented stewardship program, established volun-
tarily by British Columbia’s pharmaceutical
industry. The program’s most recent annual
report can be found in Driedger (2002). The
program was made mandatory in March 1997
by an expansion of the scope of the Post-
consumer Residual Stewardship Program
Regulation (Government of British Columbia
2002). It is designed to accept the free return
of all prescription and OTC medications (and
certain other medically oriented products); it
does not, however, accept physician samples.
The MRP derives from a true cradle-to-cradle
philosophy in that “ecology of health” is the
central focus (Daughton 2003). The MRP was
formed to balance the concerns and objectives
for ensuring or improving the health of the
environment, consumer, and economy.
The MRP has been embraced by Canada’s
National Association of Pharmacy Regulatory
Authorities (NAPRA) for a number of reasons,
including consumer/child safety (accidental
poisonings, unwitting consumption of expired
product or product prescribed for someone
else), reduced costs (encouraging purchase of
manageable drug amounts that are fully con-
sumed), improved therapeutic outcomes, and
“reduced potential for environmental damage”
(NAPRA 2002).
The Canadian take-back programs (as
founded under EnviRx) have also had unfore-
seen beneﬁts, especially for consumer health;
such collateral benefits are characteristic of
cradle-to-cradle approaches. For example, the
Alberta Pharmaceutical Association has been
mining the data compiled from their program
to answer questions regarding what consumer
sectors are discarding PPCPs and why they
are not fully using their supplies (Driver
1998). For example, a major problem long
faced by medical practitioners has been
“patient noncompliance” (why patients do
not finish their medication). The Alberta
take-back program provided the rare opportu-
nity to perform a follow-up, life-cycle analy-
sis—the type of study normally missing from
current prescribing practices. The knowledge
gained could prove extremely beneﬁcial to the
health care consumer. At the same time,
potential adverse environmental impacts are
reduced. The study learned, for example, that
geriatric patients return the most medications.
This led to the recommendation for “trial
prescriptions” that provide small initial quan-
tities, enabling the physician to determine the
suitability of the prescription for the patient
before large quantities go unused.
There are also some take-back programs in
Europe. Two major ones are Italy’s Ass.Inde
and France’s Cyclamed (e.g., Macarthur
2000). The European Agency for the
Evaluation of Medicinal Products (EMEA
2001, sec 5) also recommends that “unused
preparations or old preparations should be
returned to pharmacies.” In Australia, a free
“returns” program was launched in July 1998
using a not-for-proﬁt organization (National
Return and Disposal of Unwanted Medicines
Ltd.) in partnership with the New South
Wales Government and various pharmaceuti-
cal industry entities. Dubbed the RUM
Project (Return Unwanted Medicines), the
program plans to enlist more than 5,000 phar-
macies nationwide. As with other take-back
programs, RUM’s mission is to lessen disposal
to the environment, reduce child poisonings,
and minimize inappropriate sharing of medi-
cines (RUM 2002). A similar Australian pro-
gram is Overseas Pharmaceutical Aid for Life
(OPAL 2003)
Sparse literature. Surprisingly, the various
facets of the topic of drug disposal have been
infrequently addressed in the literature over
the years, and the few reports that have been
published in the open literature have received
little attention outside the pharmacy commu-
nity. Drug disposal has interested medical
professions primarily because of insights it
can yield on issues relating to patient compli-
ance and economic costs to the consumer.
The driving force has rarely emanated from
the potential for environmental benefits
(which are currently ill-deﬁned because of the
lack of science), although progress toward one
aim is often relevant to the other—they are
intimately tied. The two major issues in the
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(both resulting in overuse) and noncompli-
ance (resulting in discharge of unused drugs
to sewage and solid waste when a course of
medication is not completed). Inappropriate
use especially among the elderly has been a
topic of continuing debate (e.g., Gurwitz and
Rochon 2002; Pitkala et al. 2002). The pub-
lic needs to be better informed regarding the
appropriate use of medications to maximize
the benefits for themselves and the environ-
ment. The following is a synopsis of some of
these relevant studies.
Coambs et al. (1997) reported that for
Canada’s health care system, the economic
annual costs that could be potentially avoided
by better engineering of prescribing practices
and patient education (i.e., inappropriate use
and medication noncompliance) were esti-
mated to be as high as Can$7–9 billion. More
recent studies (e.g., CSHP 2002) corroborate
the economic aspects: “Misuse of drugs is not
only a major health concern, it is a major eco-
nomic concern.” In one of the earliest analy-
ses of the economic costs of drug disposal,
Kidder (1987) determined that monthly per-
patient drug wastage costs ranged from
US$1.52 to $5.67.
Boivin (1997) reports some of the only
actual survey data on drug disposal. As many
have noted, as the population age structure
becomes more inverted, the number of pre-
scriptions per patient also tends to increase;
for example, those patients 75 years and older
in 2000 received per capita the most new pre-
scriptions—an average of 12 (NACDS 2002).
But medication use not only rises with age; it
also tends to result in more wastage (for a
variety of reasons, most of which result from
issues specific to geriatric medicine). Boivin
(1997) discovered that substantial quantities
of drugs go unused from both classes of thera-
peutics—acute (short term) and maintenance
(long term). Many of the most frequently
unused (returned) drugs also happened to be
ones that have since been identified in
environmental monitoring studies (e.g.,
Daughton and Ternes 1999). Factors that
contribute to noncompliance include fre-
quent physician alterations in dosage of exist-
ing drugs and prescribing of new drugs,
patient death, patient improvement, and
silent symptoms (those that the patient can-
not detect as worsening or improving, e.g.,
high blood pressure, and that provide the
patient with no feedback or incentive for con-
tinuing with their medication). The survey
indicated that more than 63% of the popula-
tion had disposed of medication in the past.
The estimated annual cost of the wasted med-
ication across the province of Ontario
exceeded Can$40 million; if extended for all
of Canada, the wastage could have exceeded
Can$110 million. Regarding the method of
disposal (before the Canadian take-back pro-
gram), 46% had disposed of their unwanted
medications to the toilet, 31% disposed them
to trash, 17% had already been taking them
back to the pharmacy, 2% to their physician,
and 4% used other routes. The predominance
of disposal to the toilet over other routes, cor-
roborates the few other published studies,
despite claims to the contrary (e.g., Velagaleti
et al. 2002).
In a study of drug use at LTCFs, Paone et
al. (1996) make a number of recommenda-
tions regarding the reduction of medication
use. They found medication wastage to
amount to 6.7% of the total cost of dispensed
medications. This resulted partly from prob-
lematic “prn” (take as needed) medication and
because medication was discontinued by
physicians 27% of the time because it was no
longer needed or suitable; the dose of medica-
tion was altered in 5% of patients. The
researchers recommended that dispensing be
limited to 10-day (instead of 30-day) supplies.
The AMA’s Council on Scientiﬁc Affairs
addresses the issue of drug “recycling” (AMA
2001) and reaches the conclusion that the
costs associated with LTCF unused medica-
tions is between 4% and 10% of the total dis-
pensed costs. Of the wastage, more than 90%
results from “discontinuation or change in
medication or death, transfer, or hospitaliza-
tion of the resident.” But they were not able
to assess the method by which this substantial
quantity of unreturned medication was dis-
posed. The AMA encourages the use of tam-
per-evident seals on medication to facilitate
return/recycling. The AMA policy is consis-
tent with the policy of the American Society
of Consultant Pharmacists, which “supports
the return and reuse of medications to the
dispensing pharmacy to reduce the waste
associated with unused medications in LTCFs
and to offer substantial cost savings to the
health care system” (ASCP 1996).
Very sparse data are available that indicate
the quantities of drugs that are purposefully
disposed. The Australian RUM Project (RUM
2002) has recently been collecting more than
200 tons of unwanted drugs each year; this
perhaps gives a glimpse of the magnitude of
the disposal issue. In one of the only published
surveys relevant to the United States, Kuspis
and Krenzelok (1996) also surveyed commu-
nity drug disposal. Of those surveyed, only
1.4% returned medications to a pharmacy,
54% disposed of medications in the garbage,
and 35.4% flushed medications down the
toilet or sink; 7.2% did not dispose of medica-
tions, and 2% said that they used all medica-
tions before expiration. Of the pharmacies
surveyed, 97% had speciﬁc policies regarding
disposal of undispensed medications, and these
policies directed return to the producer. For
medication that was not returnable, 15% was
incinerated, 17% directed to hazardous waste
handlers, and 68% disposed to solid waste or
the toilet (but unfortunately, the two were not
distinguished). In contrast to internal operat-
ing procedures, only 5% of the surveyed phar-
macies had consistent recommendations for
their customers. Little information on safe
disposal of drugs was routinely relayed to the
public. The authors recommend that uniform
guidelines are needed for the safe disposal of
expired medications and that these policies be
included in consumer education provided by
pharmacies and poison information centers
alike. Indeed, note that the California Poison
Control System (2002) advocates flushing
unwanted drugs down the toilet. For the 12-
month period before the COMPAS survey (for
Health Canada), 19% and 20% of those sur-
veyed disposed of unused/expired nonprescrip-
tion and prescription drugs, respectively, to
sewage (with higher percentages of women
doing so than men), and 50% and 39% dis-
posed of nonprescription and prescription
drugs to the garbage, respectively (COMPAS
2002); interestingly, 26% and 37% disposed
of these by a means other than garbage,
recycling, sewage, or dumping/burying.
Only as recently as the late 1990s was the
concept of “treating the environment as our
patient” [in line with the “ecology of health”
(Daughton 2003)] beginning to emerge from
the pharmacy sector (e.g., Blanchard 1998).
Blanchard (1998) noted a survey recommen-
dation that reducing a prescription’s supply to
28 days could reduce the need for discarding
by as much as 30% (but also observed that
progress in that direction is hampered by the
desires of insurers and patients, both of whom
want bulk ﬁlling of prescriptions). Also, with
the issue of waste aside, 28-day supplies
would also reduce inappropriate use of left-
over medications and accidental poisonings
(Blanchard 1998).
Disposal Guidance
Little formal guidance has been developed for
drug disposal. The WHO was forced to
develop guidance as a result of the humanitar-
ian efforts during the Bosnia conﬂict. A major
problem arose from the enormous quantities
of expired and inappropriate medications that
were received as part of humanitarian dona-
tions. But the WHO’s (1999) guidance is
more relevant to large-scale ﬁeld situations.
The Canadian NAPRA has also taken a
proactive stance toward drug disposal (e.g.,
NAPRA 2002); their philosophy is reflected
in the consumer pamphlet prepared by the
Canadian Pharmacists Association (CPhA
2002), which gives the consumer tips on
disposal of unwanted drugs, including guid-
ance to not dispose drugs in the garbage or to
the toilet—because “it’s not good for the
environment.”
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coordinated the development of the 1998
Pharmacist Practice Activity Classification
(PPAC) system (APhA 1998), which describes
and classiﬁes the activities of licensed pharma-
cists throughout the health care delivery sys-
tem. Activity C.3.4. in the PPAC (to promote
safe medication use, storage, and disposal) has
two tasks involving drug disposal: task C.3.4.4
(educate groups about the proper disposal of
medications and devices) and task C.3.4.5
(provide a general medication and device dis-
posal service pursuant to state and federal laws
and regulations). But specifics are not
provided on their website.
For the most part, however, a large dis-
jointed patchwork of often conflicting guid-
ance and regulations exists for directing the
disposal or destruction of drugs. It has long
been common knowledge among pharmacists
and physicians, at least in some states and
locales, that oversight/regulatory authorities do
recommend “proper disposal” of drugs, but at
the same time, they contradictorily recom-
mend disposal to sewage. Oversight regarding
disposal/destruction usually resides in a variety
of agencies and departments, and those that
oversee pharmacies differ from those that
oversee nursing facilities, and yet others some-
times oversee consumer end use (Light 1997).
The importance of uniform guidance for
disposal of PPCPs is illustrated by one of the
outcomes from the American Academy of
Pediatrics (AAP) policy statement on the
implications of mercury in pediatric health care
(Goldman et al. 2001). One of the many
sources for mercury in the environment is from
personal care products and devices such as
mercury thermometers. One of the recommen-
dations set forth to pediatricians by the AAP
policy statement was for “parents to remove
mercury thermometers from their homes.”
Unfortunately, advice on the proper methods
for disposal of elemental-mercury thermome-
ters did not accompany the report. A follow-up
study (DiCarlo et al. 2002) surveyed a variety
of local, county, and state health officials to
ascertain the advice that they would be giving
to public inquirers regarding proper ther-
mometer disposal. Only 24% would have
made the correct recommendation (viz., turn
thermometers in to hazardous waste pickup).
The major (and incorrect) recommendation
would have been to dispose in domestic trash
(45%). This one example (which should have
been clear-cut) shows the importance of uni-
fied, clear guidance regarding disposal or
recycling of all medical products.
Hazardous Chemicals: A
Special and Paradoxical Case
regarding PPCPs
There does exist a special circumstance where
the disposal of speciﬁc drugs and ingredients
in personal care products is indeed regu-
lated—namely, chemicals listed as hazardous
under the Resource Conservation and
Recovery Act (RCRA 1976). The U.S.
Department of Justice’s Drug Enforcement
Agency (DEA) strictly regulates the disposal
of unwanted controlled substances (but there
are many exemptions, depending on such fac-
tors as whether the substance is used in a pre-
scription medication, e.g., pentobarbital,
phenobarbital, diazepam, codeine, and many
others). The DEA disposal program is not
discussed here; for more information, refer to
DEA (2003). The Schedules of Controlled
Substances can be obtained from the Code of
Federal Regulations (CFR 2002a). The DEA
classiﬁes controlled substances into ﬁve cate-
gories (schedules I through V), indicating
progressively lower potential for substance
abuse. Schedule I substances have a high
potential for abuse (and no recognized med-
ical uses); the other schedules contain drugs
with recognized medicinal uses.
For a drug to be RCRA listed, it generally
appears on the RCRA “P” or “U” lists. P-List
RCRA chemicals are deemed acutely haz-
ardous in any concentration (40 CFR
261.33e); U-list chemicals are deemed less
toxic (40 CFR 261.33f). Quite a number of
PPCPs appear on these two RCRA lists pri-
marily because of toxicity. In addition to P-
and U-listing, a substance is subject to RCRA
D-listing if it exhibits one or more of four
RCRA characteristics: toxicity, ignitability, cor-
rosivity, and reactivity. D-listing, however,
usually applies not to active ingredients but
rather to other ingredients (e.g., excipients such
as solvents). Some RCRA-listed chemicals that
have major medicinal therapeutic uses are
listed in Table 1 (but note that many other
nonmedicinal chemicals on these lists are com-
monly used in various other aspects of medi-
cine and therapeutics). For the complete lists,
refer to 40CFR§261.33 (CFR 2002b).
Whether a PPCP is available only by prescrip-
tion is not a determining factor for listing.
Some listed PPCP ingredients are OTC
constituents (e.g., nicotine). These issues are
further discussed by Smith (1999, 2002).
These and other commonly used PPCP
ingredients become hazardous waste at the
time the decision is made to actually dispose.
The responsibility for determining if the waste
is indeed hazardous rests with the waste gener-
ator. As mentioned above, note that for con-
trolled substances (e.g., codeine, opiates,
tranquilizers, etc.), DEA regulations apply.
Although RCRA directs the disposition of cer-
tain select PPCPs, this determines how distrib-
utors and pharmacies handle these drugs when
they are outdated. Signiﬁcantly, the law is not
closed around the complete use cycle, because
it has no impact on the actions of consumers.
For example, mention is never made on a drug
container that the ingredients are subject to
RCRA. But even then, the fact that a drug is
listed by RCRA and handled appropriately
cannot completely prevent it from entering the
environment—because the mere use of these
substances by consumers results in direct input
to the environment—by both excretion (cur-
rently unavoidable) and consumer disposal.
A paradox arises in that many regulated
industrial chemicals have dual uses—as con-
sumer nonfood products and as industrial
chemicals. These chemicals are not subject to
the same strict disposal standards for con-
sumer use as they are for industrial use.
Phthalic acid esters (phthalates) are but one
example; others include a wide array of com-
mon solvents, including alkanes, alcohols,
aldehydes, ketones, esters, and aromatics (all
of which can be used in formulating cosmetics
and for some drugs). The consequence is that
substantial exposures to very high concentra-
tions of industrially regulated substances can
result from direct application of cosmetics to
the body by unregulated consumer use.
The CDC published the first large-scale
environmental contaminant human exposure
study through direct biomonitoring of blood
and urine (Blount et al. 2000; CDC 2000b).
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Table 1. Some RCRA-listed chemicals that have major medicinal therapeutic uses.
P Lista U Listb
Epinephrine (adrenaline) P042 Chlorambucil (Leukeran) U035
Nicotine P075 Cyclophosphamide (Cytoxan, Neosar, Procytox) U058
Nitroglycerine P081 Daunomycin (Dauorubicin, Cerubidine) U059
Physostigmine P204 Diethylstilbestrol U089
Physostigmine salicylate P188 Melphalan (Alkeran) U150
Warfarin > 0.3% P001 Mitomycin C (Mutamycin) U010
Paraldehyde U182
Phenacetin U187
Reserpine U200
Saccharin U202
Selenium sulﬁde U205 (e.g., dandruff shampoos)
Streptozocin (Zanosar) U206
Uracil mustard U237
Warfarin (Coumadin) < 0.3% U248
aRepresentative P-listed drugs (some have other uses). bThe U list has a number of antineoplastic agents (among other
PPCPs).The study veriﬁed human exposure to chemi-
cals via personal care products—namely, phtha-
lates. These ubiquitous, high-volume industrial
chemicals (often used as ﬂexibility promoters in
plastics) have a plethora of end uses in con-
sumer products, including vinyl ﬂooring, wall
coverings, detergents, lubricating oils, solvents,
food packaging, and medical devices. They also
are frequently used in many formulations of
PPCPs—for example, soap, shampoo, hair
spray, sunscreens, antiperspirants, medication,
and many types of nail polish; their uses are
designed around the very abilities of phthalates
to penetrate the skin and to act as humectants
and emollients. They are incorporated into for-
mulations at high concentrations. Their use has
been so widespread for such a long time that
they are frequent background contaminants in
environmental analyses. The CDC study
showed that human exposure is higher and
spans a wider spectrum of phthalates than pre-
viously suspected. Exposure of wildlife is
unknown, but given the widespread and heavy
use of these compounds, exposures to a wide
array of organisms can be inferred.
Conclusions/Recommendations
A patchwork of inconsistent and often
conflicting advice, guidance, or regulations
exists among and within countries to guide the
disposal of PPCPs and ultimately determine
their environmental disposition. Despite this
patchwork, a wide array of actions could be
taken both near term and longer term to
lessen the introduction of PPCPs to the envi-
ronment. Given the state of current informa-
tion regarding the occurrence of PPCPs in the
environment, disposal of drugs to domestic
sewage systems is probably the least desirable
way to dispose of any drug. In the United
States, two better alternatives might include
reworking existing regulations that prevent
a) local pharmacies from taking back con-
sumer medications (to either dispose of by
medical incineration or return to “reverse dis-
tributors”) or b) local hazardous waste collec-
tors from collecting unwanted medications
(e.g., community curb-side pickup programs,
but not for RCRA- or DEA-listed PPCPs). As
a last alternative, disposal in household trash
destined for engineered landfills is probably
more environmentally sound (but still not
desirable) than disposal to sewage systems;
landﬁlls, however, are really a form of poten-
tial “pollution postponement”—as opposed to
an ultimate solution. Coincidentally, efforts to
reduce the introduction of PPCPs to the envi-
ronment often could and can have unforeseen,
collateral benefits for consumer health and
economies. Protecting the health, safety, and
pocketbook of the patient holds potential for
protecting the environment—and vice versa.
Such wide-ranging benefits are characteristic
of cradle-to-cradle stewardship programs.
Stewardship programs (centered around a
cohesive take-back or returns program) would
prove critical to the birth of the “green phar-
macy.” For true cradle-to-cradle stewardship
of PPCPs, a holistic integration of all aspects
of the production–consumption cycle is
required—one that takes into consideration
the needs and costs of the complete cycle from
drug discovery/design to distribution, end use,
and disposal/recycling. The economies and
ecological/human health efﬁciencies of no sin-
gle aspect can be optimized in isolation from
the others. Although in this mini-monograph
I survey many of the avenues for reducing the
controllable introduction of PPCPs to the
environment, I do not address the many other
issues (especially the potential for adverse
effects) associated with the unintended,
uncontrollable excretion of PPCPs and their
metabolites into the environment—a subject
of a future publication. Supplementary and
updated materials for this mini-monograph
are available at the Green Pharmacy web page
(Daughton/U.S. EPA 2003).
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